Acambis up on ACAM2000, Arilvax news

Acambis (LSE:ACM; ACAM) was up 8p to 144p on Wednesday after announcing a new order for ACAM2000 smallpox vaccine and the settlement of an Arlivax dispute. The U.S. government agreed to purchase an additional 10 million doses of the company's ACAM2000 smallpox vaccine under an existing supply contract. ACM said the order is worth about $30 million. A BLA for ACAM2000 is under FDA review with a Feb. 14, 2007, PDUFA date.

Separately, ACM said that Novartis (NVS; SWX:NOVN) agreed to pay $19 million in cash to settle a dispute regarding Arilvax yellow fever vaccine. In 1999, ACM licensed U.S. sales rights to the product from Chiron, now part of NVS. NVS also granted ACM an exclusive option to negotiate a worldwide license to the vaccine. ...